Period:
Draw Mode:
| Volume | 426,725 |
|
|||||
| News | - | ||||||
| Day High | 188.87 | Low High |
|||||
| Day Low | 184.06 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Alnylam Pharmaceuticals Inc | ALNY | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 2.26 | 1.22% | 188.26 | 00:00:03 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 186.50 | 184.06 | 188.87 | 188.26 | 186.00 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 10,630 | 426,725 | $ 187.15 | $ 79,863,705 | - | 120.43 - 242.97 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:56:45 | 38 | $ 188.26 | USD |
Alnylam Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 23.39B | 124.22M | 124.41M | $ 319.29M | $ -1.76M | -1.40 | -13,317.23 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | -26.22k | 0.10% |
Alnylam Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALNY Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 191.48 | 194.68 | 183.00 | 189.48 | 487,442 | -3.22 | -1.68% |
| 1 Month | 195.13 | 212.47 | 183.00 | 198.77 | 596,357 | -6.87 | -3.52% |
| 3 Months | 193.64 | 212.47 | 179.19 | 197.04 | 766,871 | -5.38 | -2.78% |
| 6 Months | 213.08 | 242.97 | 179.19 | 211.06 | 785,528 | -24.82 | -11.65% |
| 1 Year | 127.19 | 242.97 | 120.43 | 198.84 | 877,293 | 61.07 | 48.01% |
| 3 Years | 141.06 | 242.97 | 117.58 | 173.09 | 729,906 | 47.20 | 33.46% |
| 5 Years | 99.33 | 242.97 | 60.27 | 139.59 | 757,085 | 88.93 | 89.53% |
Alnylam Pharmaceuticals Description
| Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |